BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.9 USD | +3.18% |
|
+7.47% | -19.27% |
| 26/04 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| 25/04 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
ETFs positioned on Biogen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | -5.79% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 14,021 M€ | +4.56% | ||
| 2.28% | 4 M€ | +20.15% | ||
| 1.91% | 6 M€ | +16.84% | - | |
| 1.78% | 115 M€ | +5.90% | - | |
| 1.69% | 2 M€ | +6.77% | ||
| 1.60% | 8 M€ | +2.44% | ||
| 1.33% | 1,182 M€ | +1.06% | ||
| 1.30% | 9 M€ | -4.31% | - | |
| 1.00% | 16 M€ | -8.49% | ||
| 0.99% | 18 M€ | +3.79% | - | |
| 0.97% | 13 M€ | -.--% | - | |
| 0.97% | 3 M€ | +7.32% | - | |
| 0.97% | 1 M€ | +11.94% | - | |
| 0.94% | 204 M€ | +10.54% | ||
| 0.65% | 2 M€ | -25.75% | ||
| 0.64% | 8 M€ | +5.48% | - | |
| 0.48% | 4,592 M€ | +11.18% | ||
| 0.44% | 1 M€ | +16.32% | ||
| 0.43% | 26 M€ | +16.85% | - | |
| 0.38% | 2 M€ | +20.44% | - | |
| 0.38% | 22 M€ | 0.00% | - | |
| 0.37% | 5 M€ | -72.95% | - | |
| 0.37% | 9 M€ | -.--% | - | |
| 0.36% | 3 M€ | 0.00% | - | |
| 0.29% | 92 M€ | +0.06% | - | |
| 0.29% | 469 M€ | -2.05% | - | |
| 0.29% | 3,859 M€ | +18.82% | - | |
| 0.21% | 8 M€ | +3.41% | - |
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
208.9
USD
Average target price
286
USD
Spread / Average Target
+36.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.27% | 30.42B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- BIIB Stock
- Funds and ETFs Biogen Inc.
